Can chewing gum help America tackle the increasing opioid addiction? AXIM Biotechnologies, Inc. (AXIM Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, thinks yes, it can. And they would know, as they have just filed a patent for a product that can do just that.
Chew the pain away
Opioid addiction is currently a major problem in America. States with legalized medical cannabis have seen reduced numbers of opioid dependents seeking treatment.
AXIM Biotechnologies, Inc has just filed with the United States Patent and Trademark Office (USPTO) for U.S. Application Serial Number 62/410,469, a patent for a chewing gum composition that uses a controlled release of cannabinoids and opioid agonists and/or antagonists for dependence treatment. The chewing gum may also be used to treat chronic pain.
An agonist is a chemical that binds to a receptor and activates the receptor to produce a biological response. Full opioid agonists activate the opioid receptors in the brain resulting in the full opioid effect. Hydrocodone, Methadone, morphine, opium, and oxycodone are all full opioid agonists. However, all opioid agonists to one degree or another have side effects such as decreased respiratory drive which may lead to asphyxia, nausea and vomiting, pneumonia, constipation, etc.
An antagonist is a chemical that blocks or dampens agonist-mediated responses. Opioid antagonists block opioids by attaching to the same opioid receptors without activating them. Naltrexone and naloxone are opioid antagonists. The antagonists bind to the same receptors as agonists which remove the opioids from these sites, reducing the negative side effects of the agonists.
Opioid addiction is a serious global problem that affects the health, social, and economic welfare of all societies. Opioid addiction therapy depends on a variety of techniques.
One of them is the replacement therapy, where an opioid is replaced with another less potent and less addictive opioid that curbs the craving and reduces withdrawal symptoms, while maintaining the person’s mental state such that the person is still able to function normally. – George E. Anastassov, MD, DDS, MBA and Chief Executive Officer of AXIM Biotech
Chewing gum is safer and simpler
By providing replacement opioid agonists and/or antagonists and cannabinoids as chewing gum, the goal is that users will avoid adverse effects caused by injecting, smoking and other consumption methods.
The act of chewing is also known to be neuroprotective, destressing, it induces the release of reward hormones such as dopamine and serotonin, and improves oral health.
This is another milestone achievement for AXIM Biotech. We believe we are the first to file patent application on using chewing gum as the delivery system for opioids and combination of opioids and cannabinoids.
With this filing, we are one stop closer toward entering the $100 billion market in pain management. – Dr. Anastassov